Prognosis
Novo Nordisk Sales Soar, Fortifying Grip on Obesity Drug Market
- Wegovy sales hit nearly 10 billion kroner in the third quarter
- Company still seeking to increase supply of hit obesity drug
This article is for subscribers only.
Novo Nordisk A/S sales surged in the third quarter and double-digit growth should carry into 2024, driven by burgeoning demand for its obesity and diabetes blockbusters.
Revenue jumped 38% to 58.73 billion kroner ($8.3 billion) excluding some items, the Danish drugmaker said Thursday, strengthening its grip on an obesity market estimated to hit $100 billion by 2030. Operating profit also rose 47% during the period.